CHD Intervention Featured Articles of July 2017

Interventional Cardiology Reviews of July 2017 Manuscripts

 

A Systematic Review of Infective Endocarditis in Patients with Bovine Jugular Vein Valves Compared With Other Valve Types.

Sharma A, Cote AT, Hosking MCK, Harris KC.

JACC Cardiovasc Interv. 2017 Jul 24;10(14):1449-1458. doi: 10.1016/j.jcin.2017.04.025.

PMID: 28728659

 

Take Home Points:

  • Bovine jugular vein valves have a higher reported cummulative incidence of IE than other valve types – with no difference between surgical or transcatheter implants.
  • The data presented must be interpreted with a full understanding of the study limitations – case ascertainment bias, lack of IE definition, patient overlap and the heterogeneity of the population.
  • Providers need to be aware of the risks of IE and have an appropriate level of suspicion when managing patients with implanted pulmonary valves.

Comment from Dr., section editor of Congenital Heart Disease Interventions Journal Watch: Pulmonary valve implants are necessary for many patients with congenital heart disease and bovine jugular vein (BJV) valves, implanted via surgical (Contegra) or trans-catheter techniques (Melody valve) are widely used. Prospective Melody valve trials identified that some portion of patients experience episodes of endocarditis post-implant. The incidence of infective endocarditis (IE) relative to other valve types and method of implant (surgery vs transcatheter) is unknown. The authors sought to systematically review the published research and conduct a meta-analysis of IE incidence in RV-PA conduits, comparing BJV valves with all others and compare surgical vs transcatheter implantation techniques.

 

The authors conducted a literature review and studies were deemed eligible for inclusion if all inclusion criteria were met: patients had a pulmonary valve replacement, incidence of IE in the RVOT was reported (both number of cases and cases of IE had to be reported), method of conduit placement surgery (surgical or transcatheter), type of conduit implanted and follow up duration.

 

The systemic search identified 1,048 studies and of these 50 papers (55 study populations) with 7,063 patients were included in the final analysis. There were 5 valve types identified: Melody, Contegra, homograft, bioprosthetic (bovine pericardial, procine) and 1 nonbovine surgical valve not specified. There was a total of 181 cases of endocarditis, giving a cumulative incidence of IE of 2.6%. The median incidence of IE was higher in the BJV group compared with other valve types (5.4% v 1.2%) with no difference in the incidence of BJV valves on the basis of method of implantation.

 

There are a number of important limitations in this meta-analysis. First, there is a clear case ascertainment bias. Melody valve studies were prospective with active follow-up while the surgical series were retrospective likely resulting in greater recognition of IE in the Melody cohort. The surgical series are likely limited by an under-recognition of IE cases treated medically. In addition, most studies did not report the exact time at which IE occurred making calculation of annualized incidence as well as assessment of risk factors for development of IE nearly impossible. Second, there is not a uniform definition of IE across studies which again disadvantages the Melody valve given strict definitions of IE in the prospective follow up for Melody valve implants. Third, there is a high probability of patient overlap which the authors do not fully address. Finally, the authors do not acknowledge the heterogeneity of the patient population with clear differences in patients receiving different types of implants.

 

The authors conclude that that BJV valves have a higher reported incidence of IE than other valve types with no difference based on method of implantation. They suggest that clinicians should have a heighted awareness of IE when caring for these patients. Further research is clearly warranted to determine the pathophysiology for development of IE, risk factors and methods to decrease the incidence of IE.

 

A multicenter study of the impella device for mechanical support of the systemic circulation in pediatric and adolescent patients.

Dimas VV, Morray BH, Kim DW, Almond CS, Shahanavaz S, Tume SC, Peng LF, McElhinney DB, Justino H.

Catheter Cardiovasc Interv. 2017 Jul;90(1):124-129. doi: 10.1002/ccd.26973. Epub 2017 Mar 15.

PMID: 28295963

 

Take Home Points:

  • Preliminary findings suggest that using Impella devices for temporary circulatory support in children is feasible and efficacious.
  • 30-day mortality is high but is similar to data from Impella use in adult populations for cardiogenic shock with a similar or slightly lower complication rate.

Averin , KonstantinComment from Dr. Konstantin Averin section editor of Congenital Heart Disease Interventions Journal Watch:  In the US, FDA app averinroved options for temporary pediatric circulatory support are limited to ECMO and intra-aortic balloon pump. The Impella family of devices are now approved for short-term support for treatment of cardiogenic shock (CGS) after AMI or following open heart surgery. Off-label use of the Impella in the pediatric population has grown but the published experience to date has been limited. The authors performed a multicenter retrospective study to describe a larger pediatric experience with the Impella family of catheters, with a focus on outcomes and complications.

 

Data on 39 implants in 38 patients (≤21-year old) from 2009-2015 were included, with all but 1 patient being unique. At implant, median age was 16 years (4-21 years), median weight 62kg (15-134kg), and mean BSA 1.62 ± 0.36. The most common diagnoses were congenital heart disease (28%), post-heart transplant rejection (26%), and dilated cardiomyopathy (23%) with the most common indication for implant being ventricular dysfunction with acute CGS (28/39).

 

Patients were supported via either femoral arterial access (85%) or axillary access (15%) with a surgically placed chimney graft required in 31% of cases. Device repositioning was required in 38% of implants and median duration of support was 45 hours. 32% of patients died within 30 days of implant with half of those deaths occurring after Impella explant. Major adverse events occurred in 8 patients and included device malfunction, hemolysis, neurologic dysfunction, vascular access complications, bleeding and infection. One patient developed critical limb ischemia necessitating device removal and subsequent below the knee amputation.

As the options for temporary circulatory support expand and new data in adult populations becomes available it is important to consider whether some of these devices may be suitable for use in pediatric patients. Dimas et al, describe the largest experience to date of mechanical support with the Impella family of devices in pediatric patients with CGS. Their data suggests that the use of these devices is feasible and efficacious with an acceptable safety profile. It is of particular interest that only 2 patients had vascular access complications given the need for large bore arterial access necessary for the Impella implant. More data will clearly be necessary but this publication is an important step in expanding support options for a high-risk population.

 

Midterm to long-term safety and efficacy of self-expandable nitinol stent implantation for coarctation of aorta in adults.

Haji Zeinali AM, Sadeghian M, Qureshi SA, Ghazi P.

Catheter Cardiovasc Interv. 2017 Jul 14. doi: 10.1002/ccd.27178. [Epub ahead of print]

PMID: 28707350

 

Take Home Points:

  • Transcatheter treatment of aortic coarctation has traditionally involved balloon angioplasty and/or placement of balloon expandable stents
  • The authors present a series of 62 adolescents and adults who underwent successful placement of OptiMed Sinus-XL self-expanding nitinol stents for treatment of aortic coarctation
  • After excellent early results, the majority of patients continued to do well after an average of almost 4 years of follow-up
  • Self-expanding nitinol stents may provide benefits over these techniques of less aortic wall injury, no risk for balloon rupture during stent deployment and the potential for constant low level radial forces as the nitinol attempts to return to its nominal size

 

Comment from Dr. section editor of Congenital Heart Disease Interventions Journal Watch: Haji Zeinali and colleagues present a prospective, observational study of the use of the OptiMed Sinus-XL self-expanding nitinol stent for treating aortic coarctation in adolescents and adults. The stent is available in 16 to 34 mm diameters with a closed-cell design to optimize radial strength and is delivery through a 10-French system.

 

Patients were considered if they were over 9 years and 35 kg, had a hemodynamically significant coarctation (gradient at least 20 mmHg) and anatomy favorable to transcatheter intervention. Patients with severe coarctation underwent serial balloon dilation before stent placement. Stent sizing was 20-30% greater than the distal aortic arch at the origin of the left subclavian artery.

 

62 patients were recruited, with a mean age of 30.7 (17-63) years. All but three were native coarctations and the mean systemic systolic blood pressure was 166.7 mmHg. Stents were successfully implanted in all patients with 3 requiring an additional stent to deal with migration of the first stent. Mean pressure gradient pre-intervention was 62.4 mmHg which reduced to 2.8 mmHg after stent placement; four patients required post-dilation of the stent for residual gradients up to 15 mmHg. No major complications were reported.

 

After a mean follow-up of 45.5 months, 42 of 48 patients with systemic hypertension were either complete off medication (28 patients) or on less medical therapy (14 patients). Two patients developed significant residual aortic obstruction: the first with a 60 mmHg gradient related to neointimal proliferation was treated with repeat angioplasty and the second had a 25 mmHg gradient but refused additional treatment.

 

This study provides good longer-term data regarding the efficacy of self-expanding nitinol stents to treat aortic coarctation. A major advantage of this type is less potential aortic wall injury and the constant low level of radial force that may have some benefit in aortic remodeling over time. Also, because of the stent design, there is no chance for balloon rupture while deploying the stent. The authors stress the importance of future studies to compare surgery, balloon-expandable stents and self-expanding nitinol stents for the treatment of aortic coarctation.

 

Complete heart block following transcatheter closure of perimembranous VSD using amplatzer duct occluder II.

Ghosh S, Sridhar A, Sivaprakasam M.

Catheter Cardiovasc Interv. 2017 Jul 14. doi: 10.1002/ccd.27177. [Epub ahead of print]

PMID: 28707408

 

Take Home Points:

  • Interventional congenital cardiologists are often forced to “get creative” and make use of interventional devices for off-label indications, including transcatheter VSD closure
  • The Amplatzer Duct Occluder II has become a popular device for transcatheter perimembranous VSD closure and the authors present two patients who develop complete heart block after device placement

 

Seckler, MikeComment from Dr. Mike Seckeler (Tucson), section editor of Congenital Heart Disease Interventions Journal Watch:  Ghosh and colleagues present two illustrative cases of transcatheter perimembranous VSD closure with the Amplatzer Duct Occluder II (ADO-II). This device has emerged as a an excellent off-label device for this intervention because of its small delivery system, ease of deployment and relative “softness”, which is felt to minimize the risk of complete heart block after intervention. Unfortunately, these two patients did develop complete heart block early (<24 hours) after catheterization. The authors recognized the heart block and the patients both underwent successful surgical intervention to remove the devices and close the VSD with complete return to sinus rhythm.

 

As interventional congenital cardiologists continue to try to push the envelope and undertake more complicated transcatheter interventions, we are frequently limited by the available technology, little of which is designed with our patient population in mind. While this does allow us to exercise our creative muscles and try to find ways to fit square pegs into round holes, the above cases also remind us that sometimes complications can arise, and we need to be aware of the risks and inform our patients clearly before the procedure.

 

Intervention on Surgical Systemic-to-Pulmonary Artery Shunts: Carotid Versus Femoral Access.

Ligon RA, Ooi YK, Kim DW, Vincent RN, Petit CJ.

JACC Cardiovasc Interv. 2017 Aug 9. pii: S1936-8798(17)30972-X. doi: 10.1016/j.jcin.2017.05.023. [Epub ahead of print]

PMID: 28823774

Similar articles

Select item 28823771

 

Take Home Points:

 

  • Transcatheter interventions on Blalock-Taussig shunts (BTS) are effective and performed often, with “traditional” access approach being via the femoral artery.
  • Compared with femoral artery approach, in this study carotid artery access allowed for more successful BTS interventions and shorter time to BTS intervention.
  • Carotid artery access to the BTS for intervention should be considered more broadly and particularly in time critical situations.

 

Whiteside, WendyComment from Dr. Wendy Whiteside (Michigan), section editor of Congenital Heart Disease Interventions Journal Watch: Transcatheter interventions to treat BTS occlusion, including shunt angioplasty +/- stenting, have been demonstrated to be effective therapies to restore flow through the shunt. In some situations, in unstable patients with single source ductal dependent pulmonary blood flow, recanalization of the BTS is emergent and time sensitive.  Standard approach for these interventions has been via the femoral artery, however the carotid approach may provide a more direct route for access to the BTS.

 

Ligon et al describe their single center experience with percutaneous BTS interventions, comparing access via the femoral and carotid arteries.  Over a 5-year period, 34 patients underwent 42 BTS interventions. 32 cases began with femoral access and 10 with carotid access.  Overall, 39/42 interventions (93%) were ultimately successful with 100% success in accessing and intervening on the BTS in carotid cases and 75% success in the femoral cases.  5 initially femoral access cases were converted to carotid access during the same procedure due unsuccessful BTS intervention.  Particularly in cases with complete shunt occlusion and in a patient with saphenous vein graft and venous-valve occlusion, carotid access provided close sheath proximity and straight angle of approach contributing to successful and timely intervention.  Compared with the femoral access cohort, procedure time was lower in the carotid artery cohort (62 vs 104 minutes), time to arterial access was shorter (4 vs 9.3 minutes), time to placement of guidewire through the BTS was shorter (6.5 vs 13 minutes) and time from final sheath placement to BTS implantation was lower (9 vs 20 minutes).  There were no adverse events or complications associated with carotid artery access and no concerns for carotid patency by routine follow-up carotid ultrasound within 24 hours of access.

 

While carotid artery access has been considered in select patients and case types, the concern for embolic stroke and vascular complications has limited the more widespread use of this access site.  More recent studies, including this by Ligon et al, have found a low rate of thrombosis and risk of vascular access complications in fact lower than that with femoral access. While this is a small single center study, and while there is likely a learning curve to efficient and successful carotid artery access, the significantly shorter times to intervention in the carotid artery access reported here are notable and could be of significant importance in critically ill patients with shunt occlusion.  For efficient and direct access to the BTS, carotid artery access should be more readily considered.

      

Acute Success of Balloon Aortic Valvuloplasty in the Current Era: A National Cardiovascular Data Registry Study.

Boe BA, Zampi JD, Kennedy KF, Jayaram N, Porras D, Foerster SR, Armstrong AK.

JACC Cardiovasc Interv. 2017 Sep 11;10(17):1717-1726. doi: 10.1016/j.jcin.2017.08.001.

PMID:28882282

 

Take Home Points:

 

  • Balloon aortic valvuloplasty is considered first-line therapy for congenital aortic valve stenosis, however procedural outcomes and practice patterns across a large population have not been reassessed in the current era.
  • Using the IMPACT registry and a contemporary cohort, procedural success of balloon aortic valvuloplasty across all patients was 70%.
  • Adverse events occurred in 15.8% of patients, and were more frequent in procedures for critical vs non-critical aortic stenosis. There were no procedural deaths.

 

Comment from Dr. Wendy Whiteside (Michigan), section editor of Congenital Heart Disease Interventions Journal Watch: Large multi-center assessment of acute outcomes and practice patterns surrounding balloon aortic valvuloplasty (BAV) has not been performed since the VACA registry in the 1980-90s.  Since then, technology and procedural technique have changed significantly drawing into question the validity of this data in the current era. Using data from the IMPACT registry, a multi-center prospective registry beginning in 2011, Boe et al provided updated acute outcome data for balloon aortic valvuloplasty in isolated congenital aortic valve stenosis.

 

Over the study period from 2011-2015, a total of 1,126 balloon aortic valvuloplasty procedures were recorded in the registry (the study population consists of 1,026 procedures after exclusion for incomplete data and additional procedures performed).  Neonates <1 month) and infants (1-11 months) comprised the largest age groups at 27.4% and 25.3% respectively, with the majority of patients having non-critical aortic stenosis (89.3%) and the majority of procedures occurring in the outpatient setting (68.8%). Access site was femoral arterial in 93.9%, carotid in 4.5%, and umbilical artery in 1.1%. Median effective final balloon to aortic annulus ratio was 0.94 (IQR 0.88-1.00). Successful BAV was considered a procedure with “optimal” (peak systolic ejection gradient (PSEG) ≤35 mmHg and no AI) or “adequate” (PSEG ≤35 mmHg and 1+ (mild) aortic insufficiency or no worsening AI in patients with mixed disease at baseline) result and occurred in 70% of patients.  Unsuccessful procedures were attributed to significant AI (worse than mild, or worse than baseline) in 12.1% of procedures, residual gradient ≥35 mmHg in 11.4% of procedures, and a combination in 6.5%. In the non-critical AS group, after multivariate adjustment, unsuccessful BAV was associated with prior cardiac catheterization, higher baseline AS gradient (>60), mixed aortic valve disease worse than mild baseline AI, presence of a trainee, and >1 balloon inflation.  Overall, adverse events occurred in 15.8% of cases; major events in 11.5%. Patients with critical AS had significantly higher total and major adverse event rates, with vascular complications being the most common of these complications.  There were no procedural deaths.

 

Compared with the VACA registry data, procedural success was increased in the contemporary cohort, with a slight decrease in procedural complications and no procedural mortality.  This study compares well with recent single center studies in terms of short term outcomes. This study, however, does not address long term outcomes and its comparison to surgical aortic valvuloplasty.

 

CHD Interventions July 2017

 

  1. A Systematic Review of Infective Endocarditis in Patients With Bovine Jugular Vein Valves Compared With Other Valve Types.

Sharma A, Cote AT, Hosking MCK, Harris KC.

JACC Cardiovasc Interv. 2017 Jul 24;10(14):1449-1458. doi: 10.1016/j.jcin.2017.04.025.

PMID: 28728659

Similar articles

Select item 28737279

 

  1. Stenting complex aortic coarctation: simulation in a 3D printed model.

Pluchinotta FR, Giugno L, Carminati M.

EuroIntervention. 2017 Jul 20;13(4):490. doi: 10.4244/EIJ-D-16-00851. No abstract available.

PMID: 28169218

Similar articles

Select item 28729908

 

  1. Inaccuracy of a continuous arterial pressure waveform monitor when used for congenital cardiac catheterization.

Seckeler MD, Typpo K, Deschenes J, Higgins R, Samson R, Lichtenthal P.

Congenit Heart Dis. 2017 Jul 18. doi: 10.1111/chd.12517. [Epub ahead of print]

PMID: 28719069

Similar articles

Select item 28719049

 

  1. Pulmonary vein stenosis in patients with Smith-Lemli-Opitz syndrome.

Prosnitz AR, Leopold J, Irons M, Jenkins K, Roberts AE.

Congenit Heart Dis. 2017 Jul 18. doi: 10.1111/chd.12471. [Epub ahead of print]

PMID: 28719049

Similar articles

Select item 28721547

 

  1. The Effect on Somatic Growth of Surgical and Catheter Treatment of Secundum Atrial Septal Defects.

Chlebowski MM, Dai H, Kaine SF.

Pediatr Cardiol. 2017 Jul 18. doi: 10.1007/s00246-017-1678-6. [Epub ahead of print]

PMID: 28721547

Similar articles

Select item 28723882

 

  1. Fate of Duct-Dependent, Discontinuous Pulmonary Arteries After Arterial Duct Stenting.

Santoro G, Capozzi G, Giordano M, Gaio G, Palladino MT, Iacono C, Mahmoud HT, Russo MG.

Pediatr Cardiol. 2017 Jul 15. doi: 10.1007/s00246-017-1672-z. [Epub ahead of print]

PMID: 28711967

Similar articles

Select item 28711965

 

  1. Midterm to long-term safety and efficacy of self-expandable nitinol stent implantation for coarctation of aorta in adults.

Haji Zeinali AM, Sadeghian M, Qureshi SA, Ghazi P.

Catheter Cardiovasc Interv. 2017 Jul 14. doi: 10.1002/ccd.27178. [Epub ahead of print]

PMID: 28707350

Similar articles

 

  1. Intra-procedural continuous dialysis to facilitate interventional catheterization in pediatric patients with severe renal failure.

Opina AD, Qureshi AM, Brewer E, Elenberg E, Swartz S, Michael M, Justino H.

Catheter Cardiovasc Interv. 2017 Jul 12. doi: 10.1002/ccd.27188. [Epub ahead of print]

PMID: 28699323

Similar articles

Select item 28703426

 

  1. Temporal relationship between instantaneous pressure gradients and peak-to-peak systolic ejection gradient in congenital aortic stenosis.

Boe BA, Norris MD, Zampi JD, Rocchini AP, Ensing GJ.

Congenit Heart Dis. 2017 Jul 12. doi: 10.1111/chd.12514. [Epub ahead of print]

PMID: 28703367

Similar articles

Select item 28702947

 

  1. Can the Pulmonary Artery Wedge Pressure be Used Reliably as a Surrogate for the Left Atrial Mean Pressure in Pre-Fontan Evaluation?

Mohammad Nijres B, Abdulla RI, Awad S, Murphy J.

Pediatr Cardiol. 2017 Jul 12. doi: 10.1007/s00246-017-1681-y. [Epub ahead of print]

PMID: 28702716

Similar articles

Select item 28709660

 

  1. Risk Factors for Peri-Procedural Arterial Ischaemic Stroke in Children with Cardiac Disease.

Asakai H, Stojanovski B, Galati JC, Zannino D, Cardamone M, Hutchinson D, Cheung MMH, Mackay MT.

Pediatr Cardiol. 2017 Jul 11. doi: 10.1007/s00246-017-1674-x. [Epub ahead of print]

PMID: 28695245

Similar articles

Select item 28689504

 

  1. Noninfective Transcatheter Pulmonary Valve Thrombosis: A Rare Cause of Post-Implantation Pulmonary Valve Obstruction.

Verhoeven PA, Learn CP, Brown NM, Goldstein BH.

JACC Cardiovasc Interv. 2017 Jul 10;10(13):e119-e122. doi: 10.1016/j.jcin.2017.04.009. Epub 2017 Jun 14. No abstract available.

PMID: 28624383

Similar articles

Select item 28691263

 

  1. Stenting the vertical ductus arteriosus via axillary artery access using “wire-target” technique.

Polat TB.

Congenit Heart Dis. 2017 Jul 9. doi: 10.1111/chd.12512. [Epub ahead of print]

PMID: 28691263

Similar articles

Select item 28712562

 

  1. Lower Hospital Charges and Societal Costs for Catheter Device Closure of Atrial Septal Defects.

Sanchez JN, Seckeler MD.

Pediatr Cardiol. 2017 Jul 5. doi: 10.1007/s00246-017-1671-0. [Epub ahead of print]

PMID: 28681132

Similar articles

Select item 28681131

 

  1. Multimodality imaging for interventional cardiology.

Celi S, Martini N, Pastormerlo LE, Positano V, Berti S.

Curr Pharm Des. 2017 Jul 4. doi: 10.2174/1381612823666170704171702. [Epub ahead of print]

PMID: 28677508

Similar articles

Select item 28687271

 

  1. Anesthesia challenges in patent ductus arteriosus stenting for congenital heart disease.

Nanditha S, Kapoor PM, Sarin K.

Ann Card Anaesth. 2017 Jul-Sep;20(3):389-390. doi: 10.4103/aca.ACA_76_17. No abstract available.

PMID: 28701619 Free Article

Similar articles

Select item 28701609

 

  1. Intraoperative Stenting of Pulmonary Artery Stenosis in Children With Congenital Heart Disease.

Meot M, Lefort B, El Arid JM, Soulé N, Lothion-Boulanger J, Lengellé F, Chantepie A, Neville P.

Ann Thorac Surg. 2017 Jul;104(1):190-196. doi: 10.1016/j.athoracsur.2016.12.012. Epub 2017 Mar 6.

PMID: 28274523

Similar articles

Select item 28676203

 

  1. Comparison of self-expandable and balloon-expanding stents for hybrid ductal stenting in hypoplastic left heart complex.

Goreczny S, Qureshi SA, Rosenthal E, Krasemann T, Nassar MS, Anderson DR, Morgan GJ.

Cardiol Young. 2017 Jul;27(5):837-845. doi: 10.1017/S1047951116001347.

PMID: 28555538

Similar articles

Select item 28077189

 

  1. A multicenter study of the impella device for mechanical support of the systemic circulation in pediatric and adolescent patients.

Dimas VV, Morray BH, Kim DW, Almond CS, Shahanavaz S, Tume SC, Peng LF, McElhinney DB, Justino H.

Catheter Cardiovasc Interv. 2017 Jul;90(1):124-129. doi: 10.1002/ccd.26973. Epub 2017 Mar 15.

PMID: 28295963

Similar articles

Select item 28112463

 

  1. Circulatory support using the impella device in fontan patients with systemic ventricular dysfunction: A multicenter experience.

Morray BH, Dimas VV, Lim S, Balzer DT, Parekh DR, Van Mieghem NM, Ewert P, Kim DW, Justino H, McElhinney DB, Jones TK.

Catheter Cardiovasc Interv. 2017 Jul;90(1):118-123. doi: 10.1002/ccd.26885. Epub 2017 Jan 23.

PMID: 28112463

Similar articles

Select item 27545308

 

  1. Percutaneous closure of acute aorto-right ventricular fistula following transcatheter bicuspid aortic valve replacement.

Nakamura K, Passeri JJ, Inglessis-Azuaje I.

Catheter Cardiovasc Interv. 2017 Jul;90(1):164-168. doi: 10.1002/ccd.26705. Epub 2016 Aug 22.

PMID: 27545308

Similar articles

Select item 28696220

 

  1. Adult Congenital Interventions in Heart Failure.

Suradi HS, Hijazi ZM.

Interv Cardiol Clin. 2017 Jul;6(3):427-443. doi: 10.1016/j.iccl.2017.03.011. Review.

PMID: 28600095

Similar articles

Select item 28600089

 

  1. Invasive Hemodynamics of Adult Congenital Heart Disease: From Shunts to Coarctation.

Veeram Reddy SR, Nugent AW, Zellers TM, Dimas VV.

Interv Cardiol Clin. 2017 Jul;6(3):345-358. doi: 10.1016/j.iccl.2017.03.005. Review.

PMID: 28600089

Similar articles

Select item 28761211

 

  1. Cerebral High-Intensity Transient Signals during Pediatric Cardiac Catheterization: A Pilot Study Using Transcranial Doppler Ultrasonography.

LaRovere KL, Kapur K, McElhinney DB, Razumovsky A, Kussman BD.

J Neuroimaging. 2017 Jul;27(4):381-387. doi: 10.1111/jon.12426. Epub 2017 Jan 31.

PMID: 28140493

Similar articles

Select item 28186850

 

  1. Radiation Safety in Children With Congenital and Acquired Heart Disease: A Scientific Position Statement on Multimodality Dose Optimization From the Image Gently Alliance.

Hill KD, Frush DP, Han BK, Abbott BG, Armstrong AK, DeKemp RA, Glatz AC, Greenberg SB, Herbert AS, Justino H, Mah D, Mahesh M, Rigsby CK, Slesnick TC, Strauss KJ, Trattner S, Viswanathan MN, Einstein AJ; Image Gently Alliance.

JACC Cardiovasc Imaging. 2017 Jul;10(7):797-818. doi: 10.1016/j.jcmg.2017.04.003. Epub 2017 May 18. Review.

PMID: 28514670 Free Article

Similar articles

Select item 28765743

 

  1. Outcomes Associated with the Off-label Use of Medical Devices in Congenital Heart Disease at a Single Institute.

Kong YH, Song J, Huh J, Kang IS.

Korean Circ J. 2017 Jul;47(4):509-515. doi: 10.4070/kcj.2016.0311. Epub 2017 Jul 27.

PMID: 28765743 Free PMC Article

Similar articles

Select item 28765741

 

  1. A comparison of the in vivo neoendothelialization and wound healing processes of three atrial septal defect occluders used during childhood in a nonrandomized prospective trial.

Aydın Şahin D, Başpınar O, Sülü A, Karslıgil T, Kul S.

Anatol J Cardiol. 2017 Jul 25. doi: 10.14744/AnatolJCardiol.2017.7540. [Epub ahead of print]

PMID: 28761023 Free Article

Similar articles

Select item 28741726

 

  1. Thrombus formation 4 years after percutaneous transcatheter closure of an atrial septal defect.

Furuta A, Nagashima M, Sugiyama H, Sakamoto T, Yamazaki K.

J Card Surg. 2017 Jul 25. doi: 10.1111/jocs.13178. [Epub ahead of print] No abstract available.

PMID: 28743158

Similar articles

Select item 28707558

 

  1. Traditional Long-Term Central Venous Catheters Versus Transhepatic Venous Catheters in Infants and Young Children.

Marshall AM, Danford DA, Curzon CL, Anderson V, Delaney JW.

Pediatr Crit Care Med. 2017 Jul 25. doi: 10.1097/PCC.0000000000001276. [Epub ahead of print]

PMID: 28746169

Similar articles

Select item 28741754

 

  1. Trans-splenic Access for Portal Venous Interventions in Children: Do Benefits Outweigh Risks?

Pimpalwar S, Chinnadurai P, Hernandez A, Kukreja K, Siddiqui S, Justino H.

Cardiovasc Intervent Radiol. 2017 Jul 24. doi: 10.1007/s00270-017-1756-4. [Epub ahead of print]

PMID: 28741138

Similar articles

Select item 28736987

 

  1. Congenital heart disease and cardiac procedural outcomes in patients with trisomy 21 and Turner syndrome.

Morales-Demori R.

Congenit Heart Dis. 2017 Jul 24. doi: 10.1111/chd.12521. [Epub ahead of print]

PMID: 28736822

Similar articles

Select item 28737122

 

  1. The Cow Deserves a Fair Trial.

Jones TK.

JACC Cardiovasc Interv. 2017 Jul 24;10(14):1459-1461. doi: 10.1016/j.jcin.2017.05.057. No abstract available.

PMID: 28728660

Similar articles

 

  1. Transcatheter pulmonary valve implantation: valve technology and procedural outcome.

Salavitabar A, Flynn P, Holzer RJ.

Curr Opin Cardiol. 2017 Jul 18. doi: 10.1097/HCO.0000000000000444. [Epub ahead of print]

PMID: 28723838

Similar articles

Select item 28722763

 

  1. Complete heart block following transcatheter closure of perimembranous VSD using amplatzer duct occluder II.

Ghosh S, Sridhar A, Sivaprakasam M.

Catheter Cardiovasc Interv. 2017 Jul 14. doi: 10.1002/ccd.27177. [Epub ahead of print]

PMID: 28707408

Similar articles

Select item 28707365

 

  1. Use of 3-D digital subtraction rotational angiography during cardiac catheterization of infants and adults with congenital heart diseases.

Surendran S, Waller BR, Elijovich L, Agrawal V, Kuhls-Gilcrist A, Johnson J, Fagan T, Sathanandam SK.

Catheter Cardiovasc Interv. 2017 Jul 14. doi: 10.1002/ccd.27180. [Epub ahead of print]

PMID: 28707365

Similar articles

Select item 28708333

 

  1. Propofol versus Ketofol for Sedation of Pediatric Patients Undergoing Transcatheter Pulmonary Valve Implantation: A Double-blind Randomized Study.

Soliman R, Mofeed M, Momenah T.

Ann Card Anaesth. 2017 Jul-Sep;20(3):313-317. doi: 10.4103/aca.ACA_24_17.

PMID: 28701596 Free Article

Similar articles

Select item 28510313

 

  1. Perventricular Implantation of Melody Valve in Child With Pulmonary Hypertension After a Potts Shunt.

Mroczek T, Demkow M, Moszura T, Morka A, Skalski J.

Ann Thorac Surg. 2017 Jul;104(1):e67-e69. doi: 10.1016/j.athoracsur.2017.01.084.

PMID: 28633267

Similar articles

Select item 28633265

 

  1. Again, Two Melodies in Concert: Transcatheter Double Valve Replacement in Hedinger Syndrome.

De Rosa R, Schranz D, Zeiher AM, Fichtlscherer S.

Ann Thorac Surg. 2017 Jul;104(1):e61-e63. doi: 10.1016/j.athoracsur.2017.01.063.

PMID: 28633265

Similar articles

Select item 28318514

 

  1. Renal artery stenting in a 2-year-old child with resistant hypertension and neurofibromatosis.

Varghese K, Adhyapak SM, Lohitashwa SB, Pais P, Iyengar AA.

Cardiovasc Interv Ther. 2017 Jul;32(3):274-278. doi: 10.1007/s12928-016-0415-z. Epub 2016 Jul 22.

PMID: 27448024

Similar articles

Select item 27778147

 

  1. Hemolytic Anemia due to Right Ventricular to Pulmonary Artery Conduit Stenosis.

Rao S, Creaden JA, Gong S, Rigsby C, Costello JM.

J Pediatr Hematol Oncol. 2017 Jul;39(5):e290-e292. doi: 10.1097/MPH.0000000000000801.

PMID: 28267085

Similar articles

Select item 28652677

 

(No Ratings Yet)
Loading...Loading...


Leave a comment

Your email address will not be published. Required fields are marked *


3 + = 11